One of the most common hormonal conditions affecting women is getting a new name. In a health policy paper published in The Lancet on May 12, 2026, an international consortium of researchers, clinicians, and patient advocates announced that polycystic ovary syndrome (PCOS) will be renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The shift, set to roll out over a three-year transition period, is more than a cosmetic update — it reflects a deeper understanding of the disorder and aims to fix decades of misdiagnosis, stigma, and delayed care.
Why the Name Change Matters
The term “polycystic ovary syndrome” was coined in the 1930s, when doctors first observed clusters of small cysts on the ovaries of affected women. But research over the past several decades has revealed that the name is misleading. Studies indicate that many women diagnosed with PCOS do not actually have ovarian cysts, and many women with ovarian cysts do not have the syndrome at all. According to the National Institutes of Health, the condition affects an estimated 6% to 12% of women of reproductive age worldwide, making it one of the most prevalent endocrine disorders.
By focusing attention on the ovaries, the old name obscured what researchers now recognize as the true nature of the condition: a complex, body-wide disorder driven by insulin resistance, hormonal imbalance, and chronic inflammation.
What PMOS Stands For
The new name — Polyendocrine Metabolic Ovarian Syndrome — captures three core features of the disorder:
- Polyendocrine: Multiple hormone-producing glands are involved, including the ovaries, adrenal glands, and pancreas.
- Metabolic: The condition affects how the body processes glucose, insulin, and fats — placing it squarely in the realm of metabolic health.
- Ovarian: The ovaries remain a key affected organ, but they are no longer the sole defining feature.
Helena Teede, one of the lead authors of the consensus paper, called it “a landmark moment that will lead to desperately needed worldwide advancements in clinical practice and research.”
A Whole-Body Condition, Not Just an Ovary Problem
Research published over the past decade has consistently shown that PMOS reaches far beyond the reproductive system. Women with the condition face elevated risks for type 2 diabetes, cardiovascular disease, fatty liver disease, sleep apnea, depression, and certain cancers. By repositioning the disorder as a metabolic and endocrine condition, the medical community hopes to encourage earlier screening for these related health issues.
How PMOS Affects the Body
Three interconnected mechanisms underlie the condition, and understanding them helps explain why symptoms can feel so wide-ranging.
Insulin Resistance
Research suggests that most women with PMOS have some degree of insulin resistance, meaning their cells respond poorly to insulin. The pancreas compensates by producing more insulin, and elevated insulin levels in turn drive the ovaries to produce excess androgens (so-called “male” hormones). This feedback loop helps explain the irregular cycles, acne, and unwanted hair growth that many patients experience.
Hormonal Imbalance
Beyond elevated androgens, PMOS involves disrupted communication between the brain, ovaries, and adrenal glands. Luteinizing hormone (LH) often runs higher than follicle-stimulating hormone (FSH), interfering with ovulation. The result for many women is irregular or absent periods and difficulty conceiving.
Chronic Inflammation
Studies published in journals such as The Journal of Clinical Endocrinology & Metabolism have documented elevated inflammatory markers — including C-reactive protein and certain cytokines — in women with PMOS. This low-grade inflammation is believed to contribute to long-term cardiovascular and metabolic risk.
Long-Term Health Risks
The rename emphasizes risks that have historically been underplayed. Research suggests that women with PMOS face substantially higher odds of developing type 2 diabetes, as well as elevated risks for high cholesterol, hypertension, and endometrial cancer. According to data summarized by the World Health Organization, cardiometabolic disease is the leading cause of death among women globally — making early identification of PMOS an important preventive opportunity.
A 14-Year Process Driven by Patient Voices
The renaming was not done in a vacuum. The Global Name Change Consortium spent 14 years consulting with endocrinologists, gynecologists, primary care physicians, dermatologists, and mental health specialists. Crucially, they also surveyed more than 14,000 patients about the impact of the original name. Many reported that the term “polycystic ovary syndrome” had led to delayed diagnoses — often only flagged during fertility evaluations — and to feelings of stigma or being defined by reproductive function alone.
The consortium has set 2028 as the target year for full adoption of the new terminology in medical guidelines, electronic health records, and clinical research.
What the Rename Means for Diagnosis and Care
The diagnostic criteria themselves are not changing dramatically, but the framing is. Clinicians are being encouraged to look beyond menstrual irregularity and consider the metabolic picture from the first visit. That includes assessing fasting insulin, glucose tolerance, lipid panels, and blood pressure — not just hormone levels and ultrasound imaging.
For patients, the practical implications could be significant. Earlier identification of insulin resistance allows for earlier intervention, whether through nutrition, movement, behavioral support, or, when appropriate, medications discussed with a healthcare provider. Researchers note that the rename may also reduce diagnostic delays for women who do not have visible ovarian cysts on imaging.
Lifestyle and Evidence-Based Care
Research continues to support lifestyle changes as a cornerstone of PMOS management. Studies indicate that even modest weight loss — around 5% of body weight — can improve ovulation, insulin sensitivity, and androgen levels in many women. A Mediterranean-style dietary pattern, regular resistance and aerobic exercise, adequate sleep, and stress management all show consistent benefit in clinical trials.
Mental health support is increasingly recognized as part of comprehensive care. Women with PMOS report higher rates of anxiety and depression, and addressing these conditions can improve adherence to lifestyle interventions and overall quality of life.
The Bigger Picture
Renaming a disease is rare. Each time it happens, the goal is the same: align the language with the science so that patients get faster, more accurate, and more compassionate care.
For the millions of women living with what used to be called PCOS, the shift to PMOS is a recognition that they are dealing with a whole-body condition deserving of whole-body care. As clinical guidelines, research papers, and public health resources update over the next three years, the new framework is expected to drive better screening, more tailored treatments, and improved long-term outcomes. Women who suspect they may have PMOS — or who were previously diagnosed with PCOS — should consult a qualified healthcare provider to discuss what the updated framework means for their individual care.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.